Research Study Using 68Ga-FAPI PET Combined with Cardiac MRI to Detect and Evaluate Heart Diseases

What this Trial Is About

Cardiovascular diseases CVDs cause a significant number of deaths worldwide and remain a leading health concern, especially in China where millions suffer and die annually from these conditions. Researchers are exploring new diagnostic methods to detect myocardial fibrosis early, a key process in many CVDs. This trial investigates the use of 68Ga-FAPI PET combined with cardiac magnetic resonance imaging CMR to improve diagnosis and personalized treatment for patients with cardiovascular diseases. The study involves advanced imaging technology using 68Ga-FAPI PETCMR, which detects fibroblast activation protein FAP linked to fibrosis in the heart. Participants include a research group of 30 patients with cardiovascular diseases and 10 healthy individuals as controls. This imaging approach combines the molecular sensitivity of PET with the detailed anatomical view of CMR without additional radiation, allowing for early, comprehensive assessment of heart structure and function. Participants will undergo PET and CMR scans, with outcome measures including contrast-enhanced cardiac magnetic resonance CE-CMR, contrast-enhanced MRI CE-MRI, and PET imaging, each evaluated about two days after scanning. The study collects detailed imaging data to quantify myocardial fibrosis and assess cardiac function to better understand disease progression. Participants will be monitored throughout the study, which aims to improve cardiovascular care through innovative imaging techniques.

Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases